Colon Cancer Studies
Recently scientists have performed a colon cancer study, where patients were given lactobacilli and bifidobacteria. This study was published in the British Medical Journal (BMJ Open Gastro) July 2017.
Innovative production technique efficiently delivers, feeds and protects vigorous and non-damaged bacteria in the gastrointestinal tract for extended periods of time.
Makes it possible to use all kinds of lactobacilli or bifidobacteria strains in further research.
Developed by Wasa Medicals AB in Sweden, ProBion dry tablets were used in a 2017 human clinical study aimed at ascertaining the effect of probiotics on gut bacteria in colon cancer patients. It was found that two tablets of ProBion Clinical a day for an average of 31 days (range: 8 to 78 days) had wiped out a significant amount of cancer-associated harmful bacteria, and generated a plethora of beneficial bacteria with anti-inflammatory effects. The conclusion showed promise for using probiotics to mitigate dysbiosis and improve gut health for cancer prevention. It also showed that ProBion tablets were able to deliver and sustain undamaged probiotic bacteria in the large intestines to achieve therapeutic effect. BUY PROBION NOW
Wasa Medicals AB, based in Halmstad, Sweden, is a member of the International Probiotic Association (IPA). Led by CEO Lennart Cedgard, MD, the company developed the ProBion dry tablet matrix through collaboration with Swedish doctors and scientists, and has continuously researched probiotic dosage effect for 25 years. Dr Cedgard, who earned his medical degree from Gothenburg University Institute of Medicine, has been a general practitioner since 1982. With over 35 years clinical experience in intestinal micro-ecology, Dr Cedgard is a contributor of papers on probiotics and microbiology to medical journals. In 2016 he co-founded ProBion Innovation Sweden AB (PISA), a biotechnology research company, to study innovative use of probiotics for alleviating diseases. LEARN MORE ABOUT PISA